Table 1.
Demographic and baseline of the study population-FAS.
| Intervention group | ||||
|---|---|---|---|---|
| Variables | QW | QOW | QD | p |
| N | 187 | 185 | 176 | |
| Mean age ± SD, years | 7.8 ± 2.8 | 7.6 ± 2.7 | 8.0 ± 2.9 | 0.530 |
| Male gender, n (%) | 135 (72.2%) | 124 (67.0%) | 122 (69.5%) | 0.556* |
| Mean bone age ± SD, years | 5.6 ± 2.7 | .5.4 ± 2.6 | 5.7 ± 2.6 | 0.618 |
| Mean height ± SD, cm | 113.5 ± 14.2 | 111.7 ± 14.0 | 112.9 ± 12.9 | 0.427 |
| Mean body weight ± SD, kg | 20.7 ± 7.1 | 19.9 ± 6.0 | 20.4 ± 6.1 | 0.562 |
| Mean BMI ± SD, kg/m2 | 15.6 ± 2.1 | 15.7 ± 2.3 | 15.8 ± 1.9 | 0.482 |
| Median Ht SDSCA (Q1, Q3) | −2.75 (−3.10, −2.40) | −2.82 (−3.33, −2.39) | −2.78 (−3.37, −2.42) | 0.284# |
| Median IGF-1 (Q1, Q3), ng/ml | 100.0 (58.7, 155.0) | 94.5 (59.4, 142.0) | 88.40 (62.0, 151.0) | 0.785 |
| Median IGF-1 SDS (Q1, Q3) | −1.13 (−1.69, −0.38) | −1.04 (−1.62, −0.51) | −1.15 (−1.58, −0.72) | 0.633# |
| Median IGFBP-3 (Q1, Q3), mg/ml | 3.29 (2.58, 4.38) | 3.46 (2.36, 4.10) | 3.35 (2.72, 4.32) | 0.945 |
| Mean FPG ± SD, mmol/L | 4.6 ± 0.6 | 4.6 ± 0.6 | 4.7 ± 0.5 | 0.251 |
| Mean HbA1c ± SD, % | 5.2 ± 0.4 | 5.1 ± 0.4 | 5.2 ± 0.4 | 0.730 |
| Median TSH (Q1, Q3), mU/L | 2.70 (1.90, 3.84) | 2.62 (1.90, 3.81) | 2.68 (1.94, 4.25) | |
| Mean IGF-2 ± SD, ng/ml | 326.0 ± 109.5 | 322.7 ± 130.8 | 345.5 ± 154.9 | 0.320^ |
| Median IGFBP-2 (Q1, Q3), ng/ml | 254.2 (190.4, 334.9) | 259.7 (187.8, 338.7) | 224.2 (171.3, 310.3) | 0.082# |
BMI, body mass index; FPG, fasting plasma glucose; GH, growth hormone; HbA1c, hemoglobin A1c; Ht, height; IGF, insulin-like growth factor; IGFBP-3, insulin growth factor binding protein-3; SDS, SD scores; TSH, thyroid-stimulating hormone.
*χ2 test.
#Kruskal–Wallis test.
^ANOVA.